IL13 and eosinophilic esophagitis: QAX576, an anti-IL-13 monoclonal antibody, was tested in a small cohort of patients with proton pump inhibitor-resistant EoE for its efficacy in reducing peak eosinophil counts in the esophageal tissue after 8 weeks of treatment.